Literature DB >> 16288019

Disruption of protein kinase a regulation causes immortalization and dysregulation of D-type cyclins.

Kiran S Nadella1, Lawrence S Kirschner.   

Abstract

Phosphorylation is a key event in cell cycle control, and dysregulation of this process is observed in many tumors, including those associated with specific inherited neoplasia syndromes. We have shown previously that patients with the autosomal dominant tumor predisposition Carney complex carry inactivating mutations in the PRKAR1A gene, which encodes the type 1A regulatory subunit of protein kinase A (PKA), the cyclic AMP-dependent protein kinase. This defect was associated with dysregulation of PKA signaling, and genetic analysis has suggested that complete loss of the gene may be required for tumorigenesis. To determine the mechanism by which dysregulation of PKA causes tumor formation, we generated in vitro primary mouse cells lacking the Prkar1a protein. We report that this genetic disruption of PKA regulation causes constitutive PKA activation and immortalization of primary mouse embryonic fibroblasts (MEFs). At the molecular level, knockout of Prkar1a leads to up-regulation of D-type cyclins, and this increase occurs independently of other pathways known to increase cyclin D levels. Despite the immortalized phenotype, known mediators of cellular senescence (e.g., p53 and p19ARF) seem to remain intact in Prkar1a-/- MEFs. Mechanistically, cyclin D1 mRNA levels are not altered in the knockout cells, but protein half-life is markedly increased. Using this model, we provide the first direct genetic evidence that dysregulation of PKA promotes important steps in tumorigenesis, and that cyclin D1 is an essential target of PKA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16288019     DOI: 10.1158/0008-5472.CAN-05-3183

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

Review 1.  PRKAR1A and the evolution of pituitary tumors.

Authors:  Lawrence S Kirschner
Journal:  Mol Cell Endocrinol       Date:  2010-05-06       Impact factor: 4.102

2.  Neural crest-specific loss of Prkar1a causes perinatal lethality resulting from defects in intramembranous ossification.

Authors:  Georgette N Jones; Daphne R Pringle; Zhirong Yin; Michelle M Carlton; Kimerly A Powell; Michael B Weinstein; Ramiro E Toribio; Krista M D La Perle; Lawrence S Kirschner
Journal:  Mol Endocrinol       Date:  2010-06-09

3.  Cyclic-AMP-dependent protein kinase A regulates apoptosis by stabilizing the BH3-only protein Bim.

Authors:  Diane Moujalled; Ross Weston; Holly Anderton; Robert Ninnis; Pranay Goel; Andrew Coley; David C S Huang; Li Wu; Andreas Strasser; Hamsa Puthalakath
Journal:  EMBO Rep       Date:  2010-12-10       Impact factor: 8.807

4.  An immortalized human cell line bearing a PRKAR1A-inactivating mutation: effects of overexpression of the wild-type Allele and other protein kinase A subunits.

Authors:  Maria Nesterova; Ioannis Bossis; Feng Wen; Anelia Horvath; Ludmila Matyakhina; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2007-12-04       Impact factor: 5.958

5.  Regulation of actin function by protein kinase A-mediated phosphorylation of Limk1.

Authors:  Kiran S Nadella; Motoyasu Saji; Naduparambil K Jacob; Emilia Pavel; Matthew D Ringel; Lawrence S Kirschner
Journal:  EMBO Rep       Date:  2009-05-08       Impact factor: 8.807

6.  Glucocorticoid- and protein kinase A-dependent transcriptome regulation in airway smooth muscle.

Authors:  Anna M Misior; Deepak A Deshpande; Matthew J Loza; Rodolfo M Pascual; Jason D Hipp; Raymond B Penn
Journal:  Am J Respir Cell Mol Biol       Date:  2008-12-04       Impact factor: 6.914

Review 7.  Carney complex and McCune Albright syndrome: an overview of clinical manifestations and human molecular genetics.

Authors:  Paraskevi Salpea; Constantine A Stratakis
Journal:  Mol Cell Endocrinol       Date:  2013-09-05       Impact factor: 4.102

8.  Tissue-specific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production.

Authors:  Georgette N Jones; Chhavy Tep; William H Towns; Georgeta Mihai; Ian D Tonks; Graham F Kay; Petra M Schmalbrock; Anat O Stemmer-Rachamimov; Sung Ok Yoon; Lawrence S Kirschner
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

9.  Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes.

Authors:  Jérôme Bertherat; Anélia Horvath; Lionel Groussin; Sophie Grabar; Sosipatros Boikos; Laure Cazabat; Rosella Libe; Fernande René-Corail; Sotirios Stergiopoulos; Isabelle Bourdeau; Thalia Bei; Eric Clauser; Alain Calender; Lawrence S Kirschner; Xavier Bertagna; J Aidan Carney; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2009-03-17       Impact factor: 5.958

10.  Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53+/- or Rb1+/- backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signaling.

Authors:  Madson Q Almeida; Michael Muchow; Sosipatros Boikos; Andrew J Bauer; Kurt J Griffin; Kit Man Tsang; Chris Cheadle; Tonya Watkins; Feng Wen; Matthew F Starost; Ioannis Bossis; Maria Nesterova; Constantine A Stratakis
Journal:  Hum Mol Genet       Date:  2010-01-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.